

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:spstasxml624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

| | | | |
|--------------|---|--------|---|
| NEWS | 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS | 2 | JAN 02 | STN pricing information for 2008 now available |
| NEWS | 3 | JAN 16 | CAS patent coverage enhanced to include exemplified prophetic substances |
| NEWS | 4 | JAN 28 | USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats |
| NEWS | 5 | JAN 28 | MARPAT searching enhanced |
| NEWS | 6 | JAN 28 | USGENE now provides USPTO sequence data within 3 days of publication |
| NEWS | 7 | JAN 28 | TOXCENTER enhanced with reloaded MEDLINE segment |
| NEWS | 8 | JAN 28 | MEDLINE and LMEEDLINE reloaded with enhancements |
| NEWS | 9 | FEB 08 | STN Express, Version 8.3, now available |
| NEWS | 10 | FEB 20 | PCI now available as a replacement to DPCI |
| NEWS | 11 | FEB 25 | IFIREF reloaded with enhancements |
| NEWS | 12 | FEB 25 | IMSPRODUCT reloaded with enhancements |
| NEWS | 13 | FEB 29 | WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification |
| NEWS | 14 | MAR 31 | IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats |
| NEWS | 15 | MAR 31 | CAS REGISTRY enhanced with additional experimental spectra |
| NEWS | 16 | MAR 31 | CA/CAPLUS and CASREACT patent number format for U.S. applications updated |
| NEWS | 17 | MAR 31 | LPCI now available as a replacement to LDPCI |
| NEWS | 18 | MAR 31 | EMBASE, EMBAL, and LEMBASE reloaded with enhancements |
| NEWS | 19 | APR 04 | STN AnaVist, Version 1, to be discontinued |
| | | | |
| NEWS EXPRESS | FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008 | | |
| | | | |
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability | | |
| NEWS LOGIN | Welcome Banner and News Items | | |
| NEWS IPC8 | For general information regarding STN implementation of IPC 8 | | |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 19:53:10 ON 09 APR 2008

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 19:53:27 ON 09 APR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 APR 2008 HIGHEST RN 1012980-81-2

DICTIONARY FILE UPDATES: 8 APR 2008 HIGHEST RN 1012980-81-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10539936.str



chain nodes :

10 11 12 14 16 19



```

ring nodes :
1  2  3  4  5  6  7  8  9
chain bonds :
1-19  2-14  4-12  7-16  8-10  10-11
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-9  7-8  8-9
exact/norm bonds :
1-2  1-6  1-19  2-3  2-14  3-4  4-5  4-12  5-6  6-9  7-8  7-16  8-9  8-10  10-11
exact bonds :
5-7
isolated ring systems :
containing 1 :

```

G1:H,O,S,N

G2:O,S,N

G3:H,Cy,Ak,O,N

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:CLASS 14:CLASS 16:Atom 19:CLASS


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 H,O,S,N

G2 O,S,N

G3 H,Cy,Ak,O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam

SAMPLE SEARCH INITIATED 19:54:11 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1051 TO ITERATE

100.0% PROCESSED 1051 ITERATIONS
SEARCH TIME: 00.00.01

13 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 19076 TO 22964
PROJECTED ANSWERS: 44 TO 476

L2 13 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 19:54:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 21423 TO ITERATE

100.0% PROCESSED 21423 ITERATIONS
SEARCH TIME: 00.00.01

373 ANSWERS

L3 373 SEA SSS FUL L1

=> fil capl
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 178.82 179.03

FILE 'CAPLUS' ENTERED AT 19:54:25 ON 09 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Apr 2008 VOL 148 ISS 15
FILE LAST UPDATED: 8 Apr 2008 (20080408/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:


<http://www.cas.org/infopolicy.html>

=> s l3
L4 10 L3


=> s l4 ibib hitstr abs 1-10
MISSING OPERATOR L4 IBIB
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> d l4 ibib hitstr abs 1-10

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:661007 CAPLUS
 DOCUMENT NUMBER: 147:271414
 TITLE: Exploitation of structural and regulatory diversity in
 glutamate racemases
 AUTHOR(S): Lundqvist, Tomas; Fisher, Stewart L.; Kern, Gunther;
 Folmer, Rutger H. A.; Xue, Yafeng; Newton, D. Trevor;
 Keating, Thomas A.; Alm, Richard A.; de Jonge,
 Boudewijn L. M.
 CORPORATE SOURCE: AstraZeneca Global Structural Chemistry, AstraZeneca
 R&D Moelndal, Moelndal, SE-431 83, Swed.
 SOURCE: Nature (London, United Kingdom) (2007), 447(7146),
 817-822
 CODEN: NATUAS; ISSN: 0028-0836
 PUBLISHER: Nature Publishing Group
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 482584-49-6DP, complexes with glutamate racemase
 RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic
 preparation); BIOL (Biological study); PREP (Preparation)
 (exploitation of structural and regulatory diversity in glutamate
 racemases)
 RN 482584-49-6 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-(2-methylpropyl)-
 2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)



IT 946411-72-9P
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
 BIOL (Biological study); PREP (Preparation)
 (exploitation of structural and regulatory diversity in glutamate
 racemases)
 RN 946411-72-9 CAPLUS
 CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-
 (cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-
 d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



AB Glutamate racemase is an enzyme essential to the bacterial cell wall biosynthesis pathway, and has therefore been considered as a target for antibacterial drug discovery. We characterized the glutamate racemases of several pathogenic bacteria using structural and biochem. approaches. Here we describe three distinct mechanisms of regulation for the family of glutamate racemases: allosteric activation by metabolic precursors, kinetic regulation through substrate inhibition, and D-glutamate recycling using a D-amino acid transaminase. In a search for selective inhibitors, we identified a series of uncompetitive inhibitors specifically targeting *Helicobacter pylori* glutamate racemase that bind to a cryptic allosteric site, and used these inhibitors to probe the mechanistic and dynamic features of the enzyme. These structural, kinetic and mutational studies provide insight into the physiol. regulation of these essential enzymes and provide a basis for designing narrow-spectrum antimicrobial agents.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2005:1154366 CAPLUS

DOCUMENT NUMBER: 143:422361

TITLE: Preparation of cyclic compounds as CRF receptor antagonists

INVENTOR(S): Gyorkos, Albert Charles; Corrette, Christopher Peter; Cho, Suk Young; Turner, Timothy Mark; Aso, Kazuyoshi; Kori, Masakuni; Gyoten, Michiyo; Condroski, Kevin Ronald; Siedem, Christopher Stephen; Boyd, Steven Armen

PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan; et al.
SOURCE: PCT Int. Appl., 354 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|------------|
| WO 2005099688 | A2 | 20051027 | WO 2005-US13583 | 20050406 |
| WO 2005099688 | A3 | 20070531 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA | | | |
| CA 2562244 | A1 | 20051027 | CA 2005-2562244 | 20050406 |
| EP 1732541 | A2 | 20061220 | EP 2005-741906 | 20050406 |
| R: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, HR, LV, MK, YU | | | |
| JP 2007532580 | T | 20071115 | JP 2007-507576 | 20050406 |
| US 20070179165 | A1 | 20070802 | US 2007-593891 | 20070405 |
| PRIORITY APPLN. INFO.: | | | US 2004-560286P | P 20040407 |
| | | | WO 2005-US13583 | W 20050406 |

OTHER SOURCE(S): MARPAT 143:422361


IT 868374-31-6P, (6Z)-2-Benzyl-6-(cyclopropylimino)-3-mesityl-5-methyl-7-propyl-2,5,6,7-tetrahydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of cyclic compds. as CRF receptor antagonists with therapeutic potential)


RN 868374-31-6 CAPLUS

CN 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 6-(cyclopropylimino)-2,5,6,7-tetrahydro-5-methyl-2-(phenylmethyl)-7-propyl-3-(2,4,6-trimethylphenyl)-, (6Z)- (CA INDEX NAME)


Double bond geometry as shown.



IT 868371-84-0P, 2-Benzyl-3-(2,4-dimethylphenyl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of cyclic compds. as CRF receptor antagonists with therapeutic potential)
 RN 868371-84-0 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(2,4-dimethylphenyl)-5-methyl-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



GI




AB There are provided corticotropin-releasing factor (CRF) receptor antagonists of formula (I) and (II) [A, B = each independently 5- or 6-membered ring which may be further substituted; D = 5- or 6-membered ring which may be substituted; R1 = (un)substituted alkyl, substituted amino, hydroxy, etc.; X = CO, O, S, etc.; Y1, Y2, Q = independently (un)substituted C or N; W = a bond, (un)substituted methylene, imino, O, S, etc.; Ar = (un)substituted hetero/aryl; addnl. details are given in the claims; with the exception of certain compds.] or salts thereof or prodrugs thereof. For example, 3-(2,4-dimethylphenyl)-6-dipropylamino-5-

methyl-2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one was prepared by condensation of 6-hydrazino-3-methylpyrimidine-2,4(1H,3H)-dione (preparation given) with PhCHO, cyclization, chlorination, amination of chloride with di-Pr amine and debenzylation. CRF binding inhibitory rates are tabulated for 7 examples of I. I are useful for treating depression and anxiety (no data).

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2005:158670 CAPLUS
 DOCUMENT NUMBER: 142:261549
 TITLE: Preparation of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidine derivatives as glutamate racemase inhibitors
 INVENTOR(S): Basarab, Gregory S.; Eyermann, Charles J.; Gowravaram, Madhusudhan R.; Green, Oluyinka; Kiely, Andrew; MacPherson, Lawrence J.; Morningstar, Marshall L.; Thanh, Nguyen
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 76 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2005016929 | A1 | 20050224 | WO 2004-GB3464 | 20040812 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1664052 | A1 | 20060607 | EP 2004-743692 | 20040812 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| JP 2007502307 | T | 20070208 | JP 2006-523672 | 20040812 |
| US 20060252781 | A1 | 20061109 | US 2006-567797 | 20060209 |
| PRIORITY APPLN. INFO.: | | | US 2003-495615P | P 20030815 |
| | | | WO 2004-GB3464 | W 20040812 |

OTHER SOURCE(S): CASREACT 142:261549; MARPAT 142:261549
 IT 719298-19-8P 719298-39-2P 719298-42-7P
 719298-50-7P 719298-78-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidine derivs. as glutamate racemase inhibitors)
 RN 719298-19-8 CAPLUS
 CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-4-[(2-hydroxyethyl)amino]-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-39-2 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-6-oxo-4-thioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-42-7 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4-hydrazino-6,7-dihydro-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 719298-50-7 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[4-amino-2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-78-9 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



GI



AB Title compds. represented by the formula I [wherein A = N or (un)substituted C; R = H, halo, (un)substituted alkyl, sulfide, etc.; R2 = H, (un)substituted (cyclo)alkyl, alkenyl, aryl, etc.; R3 = (un)substituted hetero(bi)cyclic ring; and pharmaceutically acceptable salts thereof] were prepared as glutamate racemase inhibitors. For example, II was given in a multi-step synthesis starting from the reaction of 6-chlorouracil with cyclopropylmethyl bromide. I showed inhibition of glutamate racemase with IC50 values of less than 400 uM. Thus, I and their pharmaceutical compns. are useful as glutamate racemase inhibitors for the treatment or prophylaxis of H. pylori infection.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2004:589662 CAPLUS
 DOCUMENT NUMBER: 141:119326
 TITLE: Crystal structure of bacterial glutamate racemase (MurI) and the design of antibacterial agents
 INVENTOR(S): Anderson, Marie; Fisher, Stewart Lindsay; Folmer, Rutger Henk Adriaan; Kern, Gunther; Lundqvist, Rolf Tomas; Newton, David Trevor; Xue, Yafeng
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca Pharmaceuticals LP
 SOURCE: PCT Int. Appl., 1125 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|------------|
| WO 2004061097 | A2 | 20040722 | WO 2003-US38977 | 20031208 |
| WO 2004061097 | A3 | 20040923 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| US 20050037478 | A1 | 20050217 | US 2003-729571 | 20031205 |
| AU 2003302328 | A1 | 20040729 | AU 2003-302328 | 20031208 |
| EP 1573000 | A2 | 20050914 | EP 2003-810884 | 20031208 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| PRIORITY APPLN. INFO.: | | | US 2002-435087P | P 20021220 |
| | | | US 2002-435167P | P 20021220 |
| | | | US 2002-435272P | P 20021220 |
| | | | US 2002-435527P | P 20021220 |
| | | | WO 2003-US38977 | W 20031208 |
| IT 482583-54-0D, | complexes with glutamate racemase | | | |
| 482583-72-2D, | complexes with glutamate racemase | | | |
| 482583-80-2D, | complexes with glutamate racemase | | | |
| 482583-92-6D, | complexes with glutamate racemase | | | |
| 482584-43-0D, | complexes with glutamate racemase | | | |
| 482584-49-6D, | complexes with glutamate racemase | | | |
| 482584-60-1D, | complexes with glutamate racemase | | | |
| 482584-67-8D, | complexes with glutamate racemase | | | |
| 482584-95-2D, | complexes with glutamate racemase | | | |
| 482585-01-3D, | complexes with glutamate racemase | | | |
| 482585-68-2D, | complexes with glutamate racemase | | | |
| 482585-73-9D, | complexes with glutamate racemase | | | |
| 482586-39-0D, | complexes with glutamate racemase | | | |
| 482586-96-9D, | complexes with glutamate racemase | | | |
| 482587-04-2D, | complexes with glutamate racemase | | | |
| 482587-09-7D, | complexes with glutamate racemase | | | |
| 482587-14-4D, | complexes with glutamate racemase | | | |
| 719298-33-6D, | complexes with glutamate racemase | | | |
| 719298-34-7D, | complexes with glutamate racemase | | | |


719298-35-8D, complexes with glutamate racemase
 723265-96-1D, complexes with glutamate racemase
 723265-99-4D, complexes with glutamate racemase
 723266-01-1D, complexes with glutamate racemase
 723266-03-3D, complexes with glutamate racemase
 723266-05-5D, complexes with glutamate racemase
 723266-08-8D, complexes with glutamate racemase
 723266-12-4D, complexes with glutamate racemase
 723266-19-1D, complexes with glutamate racemase
 723266-22-6D, complexes with glutamate racemase

RL: BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(crystal structure of bacterial glutamate racemase (MurI) and the design of antibacterial agents)


RN 482583-54-0 CAPLUS

CN Acetamide, N-[4-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]- (CA INDEX NAME)



RN 482583-72-2 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-(dimethylamino)ethyl]-1-methyl- (CA INDEX NAME)



RN 482583-80-2 CAPLUS


CN 1H-Pyrrole-3-carboxylic acid, 1-methyl-5-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-

d]pyrimidin-3-yl]-, methyl ester (CA INDEX NAME)




RN 482583-92-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482584-43-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482584-49-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)



RN 482584-60-1 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)-5-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 482584-67-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-[(3,5-dimethyl-4-isoxazolyl)methyl]-5-methyl-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 482584-95-2 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-methyl-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)- (CA INDEX NAME)




RN 482585-01-3 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-[3-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 482585-68-2 CAPLUS

CN 1H-Imidazole-4-sulfonamide, 2-[2-[(5-chloro-1-(methylsulfonyl)-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482585-73-9 CAPLUS

CN 1H-Imidazole-4-sulfonamide, 1-methyl-2-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482586-39-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-fluorobenzo[b]thien-3-yl)methyl]-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-96-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482587-04-2 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)-5-[2-(1H-pyrazol-1-yl)ethyl]- (CA INDEX NAME)



RN 482587-09-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-


quinolinyl)methyl]-7-(2-methylpropyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)-5-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 482587-14-4 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-3-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-methyl-2-(1-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 719298-33-6 CAPLUS

CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 4-amino-2,7-dihydro-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 719298-34-7 CAPLUS

CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 2,7-dihydro-4-(methylamino)-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)



RN 719298-35-8 CAPLUS


CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 4-(dimethylamino)-2,7-dihydro-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)



RN 723265-96-1 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)-2-[(3-phenyl-1H-pyrazol-4-yl)methyl]-

(CA INDEX NAME)




RN 723265-99-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(3-pyridinyl)- (CA INDEX NAME)




RN 723266-01-1 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(2,3-dichlorophenyl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-naphthalenylmethyl)- (CA INDEX NAME)




RN 723266-03-3 CAPLUS

CN Benzoic acid, 3-[7-(cyclobutylmethyl)-4,5,6,7-tetrahydro-5-methyl-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 723266-05-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)- (CA INDEX NAME)




RN 723266-08-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)-2-(4-quinoliny)methyl)- (CA INDEX NAME)




RN 723266-12-4 CAPLUS

CN 5H-Pyrazolo[3,4-d]pyrimidine-5-acetamide, 2,4,6,7-tetrahydro-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-3-(4-pyridinyl)- (CA INDEX NAME)




RN 723266-19-1 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-(benzo[b]thien-3-ylmethyl)-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-, methyl ester (CA INDEX NAME)



RN 723266-22-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-fluoro-1H-indol-3-yl)methyl]dihydro-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (9CI) (CA INDEX NAME)




AB The present invention discloses crystals of glutamate racemase (MurI) from Gram-neg., Gram-pos., and atypical bacteria. The crystal lattice parameters and atomic coordinates are provided for MurI enzymes from *Helicobacter pylori*, *Escherichia coli*, *Enterococcus faecalis*, *Enterococcus faecium*, and *Staphylococcus aureus*, and with MurI enzymes complexed with activator (UDP-MurNAc-Ala) or pyrimidinedione inhibitors. Computer-assisted method for screening, identifying, and designing inhibitors of MurI with MIC values of ≤ 8 $\mu\text{g/mL}$ and K_d of ≤ 1 μM and their use for treatment of bacterial infections are provided./.

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2004:546511 CAPLUS
 DOCUMENT NUMBER: 141:106488
 TITLE: Preparation of pyrazolo[3,4-d]pyrimidine derivatives
 for treatment of H.pylori infection
 INVENTOR(S): Basarab, Gregory; Eyermann, Joseph; Gowravaram,
 Madhusudhan; Green, Oluyinka; Macpherson, Lawrence;
 Morningstar, Marshall; Nguyen, Thanh
 PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.
 SOURCE: PCT Int. Appl., 129 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2004056831 | A1 | 20040708 | WO 2003-SE2033 | 20031219 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2003288869 | A1 | 20040714 | AU 2003-288869 | 20031219 |
| EP 1585748 | A1 | 20051019 | EP 2003-781250 | 20031219 |
| EP 1585748 | B1 | 20061227 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| JP 2006512366 | T | 20060413 | JP 2004-562221 | 20031219 |
| AT 349448 | T | 20070115 | AT 2003-781250 | 20031219 |
| ES 2278211 | T3 | 20070801 | ES 2003-781250 | 20031219 |
| US 20070004761 | A1 | 20070104 | US 2006-539936 | 20060505 |
| PRIORITY APPLN. INFO.: | | | SE 2002-3825 | A 20021220 |
| | | | WO 2003-SE2033 | W 20031219 |

OTHER SOURCE(S): MARPAT 141:106488
 IT 719298-23-4P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of pyrazolo[3,4-d]pyrimidine derivs. for treatment of H.pylori infection)
 RN 719298-23-4 CAPLUS
 CN 1H-Pyrrole-3-carbonitrile, 5-[4-amino-2-[(6-chloro-4-quinolinyl)methyl]-6,7-dihydro-7-(2-methylpropyl)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




IT 719298-19-8P 719298-20-1P 719298-21-2P
 719298-22-3P 719298-24-5P 719298-25-6P
 719298-26-7P 719298-27-8P 719298-28-9P
 719298-29-0P 719298-30-3P 719298-31-4P
 719298-33-6P 719298-34-7P 719298-35-8P
 719298-37-0P 719298-38-1P 719298-39-2P
 719298-40-5P 719298-41-6P 719298-42-7P
 719298-43-8P 719298-44-9P 719298-45-0P
 719298-46-1P 719298-47-2P 719298-50-7P
 719298-51-8P 719298-52-9P 719298-53-0P
 719298-54-1P 719298-55-2P 719298-56-3P
 719298-57-4P 719298-58-5P 719298-59-6P
 719298-60-9P 719298-61-0P 719298-62-1P
 719298-64-3P 719298-65-4P 719298-66-5P
 719298-67-6P 719298-68-7P 719298-69-8P
 719298-70-1P 719298-71-2P 719298-73-4P
 719298-74-5P 719300-37-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of pyrazolo[3,4-d]pyrimidine derivs. for treatment of H.pylori infection)

RN 719298-19-8 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-4-[(2-hydroxyethyl)amino]-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-20-1 CAPLUS
 CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-4-[(2-hydroxypropyl)amino]-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



RN 719298-21-2 CAPLUS
 CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-4-[(2-hydroxy-1-methylethyl)amino]-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-22-3 CAPLUS
 CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-4-[(3-hydroxypropyl)amino]-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-24-5 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-6,7-dihydro-4-(methylamino)-7-(2-methylpropyl)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-25-6 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4-(dimethylamino)-6,7-dihydro-7-(2-methylpropyl)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-26-7 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-6,7-dihydro-7-(2-methylpropyl)-6-oxo-4-(propylamino)-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-27-8 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-6,7-dihydro-4-(hydroxyamino)-7-(2-methylpropyl)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-28-9 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4-(cyclopropylamino)-6,7-dihydro-7-(2-methylpropyl)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-29-0 CAPLUS

CN 1H-Pyrrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-6,7-dihydro-4-[(2-hydroxyethyl)amino]-7-(2-methylpropyl)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-30-3 CAPLUS

CN 1H-Pyrrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4-hydrazino-6,7-dihydro-7-(2-methylpropyl)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 719298-31-4 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4-(2,2-dimethylhydrazino)-6,7-dihydro-7-(2-methylpropyl)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 719298-33-6 CAPLUS


CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 4-amino-2,7-dihydro-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)



RN 719298-34-7 CAPLUS


CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 2,7-dihydro-4-(methylamino)-7-(2-

methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 719298-35-8 CAPLUS

CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 4-(dimethylamino)-2,7-dihydro-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 719298-37-0 CAPLUS

CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 4-amino-2-[(6-chloro-4-quinolinyl)methyl]-2,7-dihydro-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)- (CA INDEX NAME)




RN 719298-38-1 CAPLUS

CN Acetamide, N-[2-[(6-chloro-4-quinolinyl)methyl]-3-(4-cyano-1-methyl-1H-pyrrol-2-yl)-6,7-dihydro-7-(2-methylpropyl)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-4-yl]- (CA INDEX NAME)




RN 719298-39-2 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-6-oxo-4-thioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-40-5 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-4-(methylthio)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-41-6 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



RN 719298-42-7 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4-hydrazino-6,7-dihydro-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 719298-43-8 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-4-[[(2S)-2-hydroxypropyl]amino]-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 719298-44-9 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-4-[[(2R)-2-hydroxypropyl]amino]-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 719298-45-0 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[6-amino-2-[(6-chloro-4-quinolinyl)methyl]-4,5-dihydro-5-methyl-4-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-46-1 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-6-imino-5-methyl-4-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-47-2 CAPLUS

CN Butanamide, N-[2-[(6-chloro-4-quinolinyl)methyl]-3-(4-cyano-1-methyl-1H-pyrrol-2-yl)-4,5-dihydro-5-methyl-4-oxo-2H-pyrazolo[3,4-d]pyrimidin-6-yl]-3-methyl- (CA INDEX NAME)



RN 719298-50-7 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 5-[4-amino-2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



RN 719298-51-8 CAPLUS

CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-2,4,5,7-tetrahydro-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-4-thioxo- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 719298-52-9 CAPLUS


CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-2,4,5,7-tetrahydro-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-4-(methylimino)-, (4Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 719298-53-0 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-4-imino-5-methyl-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



RN 719298-54-1 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 5-[(4Z)-2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4-(methylimino)-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 719298-55-2 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4-oxo-6-thioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



RN 719298-56-3 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[(6Z)-2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-6-(methylimino)-4-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 719298-57-4 CAPLUS

CN Acetamide, N-[2-[(6-chloro-4-quinolinyl)methyl]-3-(4-cyano-1-methyl-1H-pyrrol-2-yl)-7-(cyclopropylmethyl)-2,4,5,7-tetrahydro-5-methyl-4-oxo-6H-pyrazolo[3,4-d]pyrimidin-6-ylidene]-, [N(Z)]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 719298-58-5 CAPLUS

CN Methanesulfonamide, N-[2-[(6-chloro-4-quinolinyl)methyl]-3-(4-cyano-1-methyl-1H-pyrrol-2-yl)-7-(cyclopropylmethyl)-2,4,5,7-tetrahydro-5-methyl-4-oxo-6H-pyrazolo[3,4-d]pyrimidin-6-ylidene]-, [N(Z)]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 719298-59-6 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 5-[(6Z)-2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6-[[2-(dimethylamino)ethyl]imino]-4,5,6,7-tetrahydro-5-methyl-4-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 719298-60-9 CAPLUS

CN Acetamide, N-[2-[(6-chloro-4-quinolinyl)methyl]-3-(4-cyano-1-methyl-1H-pyrrol-2-yl)-7-(cyclopropylmethyl)-2,4,5,7-tetrahydro-5-methyl-4-oxo-6H-pyrazolo[3,4-d]pyrimidin-6-ylidene]-2-(dimethylamino)- (CA INDEX NAME)




RN 719298-61-0 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-62-1 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-64-3 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-6-[(cyclopropylmethyl)amino]-4,5-dihydro-5-methyl-4-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-65-4 CAPLUS

CN 1-Propanesulfonamide, N-[2-[(6-chloro-4-quinolinyl)methyl]-3-(4-cyano-1-methyl-1H-pyrrol-2-yl)-4,5-dihydro-5-methyl-4-oxo-2H-pyrazolo[3,4-d]pyrimidin-6-yl]- (CA INDEX NAME)




RN 719298-66-5 CAPLUS

CN Carbamic acid, [2-[(6-chloro-4-quinolinyl)methyl]-3-(4-cyano-1-methyl-1H-pyrrol-2-yl)-4,5-dihydro-5-methyl-4-oxo-2H-pyrazolo[3,4-d]pyrimidin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 719298-67-6 CAPLUS


CN Urea, N-[2-[(6-chloro-4-quinolinyl)methyl]-3-(4-cyano-1-methyl-1H-pyrrol-2-yl)-4,5-dihydro-5-methyl-4-oxo-2H-pyrazolo[3,4-d]pyrimidin-6-yl]-N'-ethyl- (CA INDEX NAME)



RN 719298-68-7 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 5-[(4Z)-2-[(6-chloro-4-quinolinyl)methyl]-6-[(cyclopropylmethyl)amino]-4,5-dihydro-5-methyl-4-(methylimino)-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 719298-69-8 CAPLUS
 CN 1H-Pyrrole-3-carbonitrile, 5-[(4Z,6Z)-2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-bis(methylimino)-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 719298-70-1 CAPLUS
 CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-4-[(2-hydroxybutyl)amino]-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-71-2 CAPLUS
 CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-6,7-dihydro-4-methoxy-6-oxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-73-4 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-6-[(cyclopropylmethyl)amino]-4-(methylamino)-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 719298-74-5 CAPLUS

CN Cyclopropaneacetamide, N-[3-(4-acetyl-1-methyl-1H-pyrrol-2-yl)-2-[(6-chloro-4-quinolinyl)methyl]-4-methoxy-2H-pyrazolo[3,4-d]pyrimidin-6-yl]- (CA INDEX NAME)




RN 719300-37-5 CAPLUS


CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,7-dihydro-6-(methylamino)-4-(methylimino)-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (9CI) (CA INDEX NAME)



IT 719298-78-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of pyrazolo[3,4-d]pyrimidine derivs. for treatment of H.pylori infection)
 RN 719298-78-9 CAPLUS
 CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




IT 482583-68-6, 7-Isobutyl-2-(1-naphthylmethyl)-3-pyridin-4-yl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-30-4,
 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrazolo[3,4-d]pyrimidine derivs. for treatment of H.pylori infection)
 RN 482583-68-6 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)



RN 482587-30-4 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I-IV [wherein X = S, O, or NR20, with exclusions; W = S, O, or NR20, with an exclusion; R1 = H, (un)substituted alkyl, alkenyl, etc.; R2 = H, (un)substituted alkyl, alkenyl, etc.; R3 = (hetero)cycllyl; R4 = (hetero)cycllyl; R20 = H, CN, (un)substituted alkyl, etc.] or pharmaceutically acceptable salts thereof are prepared for the treatment or prophylaxis of H. pylori infection. For example, the compound V was prepared in a multi-step synthesis. These compds. showed IC50 of <400 μM against glutamate racemase.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2003:22881 CAPLUS
 DOCUMENT NUMBER: 138:89821
 TITLE: Preparation of pyrazolo[3,4-d]pyrimidines for
 inhibiting H. pylori infections
 INVENTOR(S): Basarab, Gregory; Eyermann, Joseph; Gowravaram,
 Madhusudhan; Green, Oluyinka; MacPherson, Lawrence;
 Morningstar, Marshall; Nguyen, Thanh
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
 SOURCE: PCT Int. Appl., 240 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|--|----------|--------------------------------|--------------------------|
| WO 2003002567 | A1 | 20030109 | WO 2002-SE1303 | 20020628 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| AU 2002315992 | A1 | 20030303 | AU 2002-315992 | 20020628 |
| EP 1412355 | A1 | 20040428 | EP 2002-746256 | 20020628 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | |
| JP 2004521944 | T | 20040722 | JP 2003-508948 | 20020628 |
| US 20040254183 | A1 | 20041216 | US 2004-481178 | 20040614 |
| US 7285558 | B2 | 20071023 | | |
| PRIORITY APPLN. INFO.: | | | SE 2001-2315 WO 2002-SE1303 | A 20010628 W 20020628 |
| OTHER SOURCE(S): | MARPAT 138:89821 | | | |
| IT 482583-70-0P, | 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylic acid 482583-73-3P | | | |
| 482583-86-8P, | 5-[7-(Cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylic acid 482583-87-9P, | | | |
| 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylic acid 482583-88-0P, | 5-[7-Isobutyl-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylic acid 482583-89-1P, | | | |
| 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylic acid 482583-90-4P, | 5-[2-(1-Benzothien-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylic acid 482584-39-4P, | | | |
| 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(trifluoroacetyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-56-5P, | 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4- | | | |


d]pyrimidine-4,6(5H,7H)-dione 482584-70-3P, 3-[7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]benzoic acid 482584-98-5P, 5-Methyl-2-[(naphth-1-yl)methyl]-3-(4-pyridinyl)-7-[[[trifluoromethyl)sulfanyl]methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-00-2P, 5-Methyl-7-[(methylthio)methyl]-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-01-3P, 7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-3-[3-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-02-4P 482585-47-7P, N-(tert-Butyl)-2-[7-isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazole-4-sulfonamide 482585-53-5P, N-(tert-Butyl)-3-[7-isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]benzenesulfonamide 482585-71-7P, N-(tert-Butyl)-2-[7-isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-imidazole-4-sulfonamide 482585-72-8P, N-(tert-Butyl)-3-[7-isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methylbenzenesulfonamide 482585-74-0P, 2-[7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazole-4-sulfonamide trifluoroacetate (1:1) 482585-75-1P, 3-[7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]benzenesulfonamide 482587-08-6P, 2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(antibacterial agent; preparation of pyrazolo[3,4-d]pyrimidine H. pylori antibacterial agents by cyclocondensation of pyrimidinylhydrazones with aldehydes)


RN 482583-70-0 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482583-73-3 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(3-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482583-86-8 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482583-87-9 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(5-chloro-1H-indazol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482583-88-0 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 1-methyl-5-[4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482583-89-1 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482583-90-4 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 2-[2-(benzo[b]thien-3-ylmethyl)-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482584-39-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(trifluoroacetyl)-1H-pyrrol-2-yl]- (9CI) (CA INDEX NAME)




RN 482584-56-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482584-70-3 CAPLUS

CN Benzoic acid, 3-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482584-98-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)-7-[[trifluoromethylthio]methyl]- (CA INDEX NAME)




RN 482585-00-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-[(methylthio)methyl]-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482585-01-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-[3-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 482585-02-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-2-(1-naphthalenylmethyl)-7-[(phenylthio)methyl]-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482585-47-7 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-(1,1-dimethylethyl)-1-methyl-2-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482585-53-5 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482585-71-7 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-(1,1-dimethylethyl)-N,1-dimethyl-2-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)



RN 482585-72-8 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-N-methyl-3-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482585-74-0 CAPLUS

CN 1H-Imidazole-4-sulfonamide, 1-methyl-2-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 482585-73-9

CMF C25 H27 N7 O4 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 482585-75-1 CAPLUS

CN Benzenesulfonamide, 3-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)



RN 482587-08-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-7-(2-methylpropyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)- (CA INDEX NAME)

Page 62

482583-85-7P, Methyl 5-[7-(cyclopropylmethyl)-2-[(5-ethyl-1H-indol-3-yl)methyl]-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylate 482583-91-5P, 5-[2-[(5-Chloro-1H-indazol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylic acid 482583-92-6P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-carboxamide 482583-93-7P, N-Cyclopropyl-5-[7-(cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxamide 482583-94-8P, 5-[7-(Cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl-1H-pyrrole-3-carboxamide 482583-95-9P 482583-97-1P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl-1H-pyrrole-3-carboxamide 482583-98-2P, 5-[7-(Cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-carboxamide 482583-99-3P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-(dimethylamino)ethyl]-1-methyl-1H-pyrrole-3-carboxamide 482584-00-9P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-cyclopropyl-1-methyl-1H-pyrrole-3-carboxamide 482584-01-0P, 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl-1H-pyrrole-3-carboxamide 482584-03-2P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-[3-(4-methylpiperazin-1-yl)propyl]-1H-pyrrole-3-carboxamide 482584-04-3P, N-(2-Aminoethyl)-5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxamide 482584-05-4P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-isopropyl-1-methyl-1H-pyrrole-3-carboxamide 482584-06-5P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[3-(1H-imidazol-1-yl)propyl]-1-methyl-1H-pyrrole-3-carboxamide 482584-07-6P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-(2-hydroxyethyl)-1-methyl-1H-pyrrole-3-carboxamide 482584-08-7P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-(2-(morpholin-4-yl)ethyl)-1H-pyrrole-3-carboxamide 482584-09-8P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-[2-(methylsulfonyl)ethyl]-1H-pyrrole-3-carboxamide 482584-10-1P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl-1H-pyrrole-3-carboxamide 482584-11-2P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-(2-methoxyethyl)-1-methyl-1H-pyrrole-3-carboxamide 482584-12-3P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-(pyridin-4-ylmethyl)-1H-pyrrole-3-carboxamide 482584-13-4P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-

methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-
 (isopropylamino)ethyl]-1-methyl-1H-pyrrole-3-carboxamide
 482584-14-5P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-
 methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-
 methyl-1H-pyrrole-3-carboxamide 482584-15-6P,
 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-
 dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-cyclopropyl-1-
 methyl-1H-pyrrole-3-carboxamide 482584-16-7P,
 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-
 dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-
 (dimethylamino)ethyl]-1-methyl-1H-pyrrole-3-carboxamide
 482584-17-8P, 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-
 (cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-
 d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-carboxamide
 482584-18-9P, N-Cyclopropyl-5-[7-isobutyl-5-methyl-2-[(5-methyl-1H-
 indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-
 d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxamide 482584-19-0P
 , 5-[7-Isobutyl-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-
 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl-1H-
 pyrrole-3-carboxamide 482584-20-3P, 5-[7-Isobutyl-5-methyl-2-[(5-
 methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-
 d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-carboxamide
 482584-21-4P, 5-[2-[(5-Chloro-1H-indazol-3-yl)methyl]-7-
 (cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-
 d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-carboxamide
 482584-22-5P, 5-[2-[(5-Chloro-1H-indazol-3-yl)methyl]-7-
 (cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-
 d]pyrimidin-3-yl]-N-cyclopropyl-1-methyl-1H-pyrrole-3-carboxamide
 482584-23-6P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-
 methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-
 methyl-1H-pyrrole-3-carboxamide
 482584-24-7P, 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-
 methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-
 cyclopropyl-1-methyl-1H-pyrrole-3-carboxamide 482584-25-8P,
 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-
 tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl-1H-pyrrole-
 3-carboxamide 482584-26-9P, 5-[2-[(6-Chloroquinolin-4-yl)methyl]-
 7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-
 d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-carboxamide
 482584-27-0P, 5-[2-[(1-Benzothien-3-yl)methyl]-7-isobutyl-5-methyl-
 4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-
 (dimethylamino)ethyl]-1-methyl-1H-pyrrole-3-carboxamide
 482584-28-1P, 5-[2-[(1-Benzothien-3-yl)methyl]-7-isobutyl-5-methyl-
 4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-
 dimethyl-1H-pyrrole-3-carboxamide 482584-29-2P,
 N-[2-(Dimethylamino)ethyl]-5-[7-isobutyl-5-methyl-2-[(5-methyl-1H-indol-3-
 yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-
 1-methyl-1H-pyrrole-3-carboxamide 482584-30-5P,
 2-(Dimethylamino)ethyl 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-
 methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-
 methyl-1H-pyrrole-3-carboxylate 482584-31-6P,
 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-
 tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-(dimethylamino)ethyl]-1-
 methyl-1H-pyrrole-3-carboxamide 482584-32-7P,
 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-3-[1-methyl-4-
 (piperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-
 6,5(H,7H)-dione 482584-33-8P, 5-[2-[(5-Chloro-1H-indol-3-
 yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-
 pyrazolo[3,4-d]pyrimidin-3-yl]-N,N,1-trimethyl-1H-pyrrole-3-carboxamide

482584-34-9P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile 482584-35-0P, 5-[7-(Cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile 482584-36-1P, 5-[7-Isobutyl-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile 482584-37-2P, 3-(4-Acetyl-1-methyl-1H-pyrrol-2-yl)-2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-38-3P, 3-(4-Acetyl-1-methyl-1H-pyrrol-2-yl)-2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-41-8P, 5-Methyl-2-[(naphth-1-yl)methyl]-7-neopentyl-3-(pyridin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-42-9P, 5-[2-[(5-Chloro-1H-imidazol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile 482584-43-0P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-44-1P, 7-Isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-[(5-nitro-1H-indol-3-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-45-2P, 2-[(5-Chloro-2-methyl-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-46-3P, 7-Isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-[(5-methyl-1H-indol-3-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-47-4P, 7-Isobutyl-5-methyl-3-(1-methyl-1H-pyrrol-2-yl)-2-[(naphth-1-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-48-5P, 5-[7-Isobutyl-5-methyl-2-[(2-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile 482584-49-6P, 7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-50-9P, 2-(1-Benzothien-3-ylmethyl)-7-isobutyl-5-methyl-3-(3-methylthien-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-51-0P, 3-[[7-Isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl]methyl]-1H-indole-5-carbonitrile 482584-52-1P, 7-Isobutyl-2-[(5-methoxy-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-53-2P, 7-Isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-[(4-methyl-1H-indol-3-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-54-3P, 7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-3-thien-2-yl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-55-4P, 2-(1-Benzothien-3-ylmethyl)-7-isobutyl-5-methyl-3-(pyridin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-57-6P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-3-(1-methyl-1H-imidazol-2-yl)-5-(2-(morpholin-4-yl)ethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-58-7P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-5-(2-hydroxyethyl)-7-isobutyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-59-8P, 7-Isobutyl-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-5-(pyridin-3-ylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-60-1P, 7-Isobutyl-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-5-(pyridin-4-ylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-61-2P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-5-methyl-7-(3-methylbutyl)-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-62-3P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclobutylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-

d]pyrimidine-4,6(5H,7H)-dione 482584-64-5P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-[(3,5-dimethylisoxazol-4-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-65-6P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-propyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-66-7P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-5-methyl-7-(2-methylbenzyl)-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-67-8P, 7-[(3,5-Dimethylisoxazol-4-yl)methyl]-5-methyl-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-68-9P, 7-(4-Hydroxybenzyl)-5-methyl-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-69-0P, 3-[(5-Methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-3-(pyridin-4-yl)-2,4,5,6-tetrahydro-7H-pyrazolo[3,4-d]pyrimidin-7-yl)methyl]benzoic acid 482584-71-4P, 3-[7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]benzamide 482584-72-5P, 3-[5-Methyl-7-(3-methylbutyl)-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]benzoic acid 482584-74-7P, 3-[7-(Cyclopropylmethyl)-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]benzoic acid 482584-75-8P, 3-(4-Amino-1-methyl-1H-imidazol-2-yl)-2-(benzothien-3-ylmethyl)-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-77-0P, N-[2-[2-(Benzothien-3-ylmethyl)-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazol-4-yl]acetamide 482584-79-2P, tert-Butyl [2-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazol-4-yl]carbamate 482584-80-5P, 3-(4-Amino-1-methyl-1H-imidazol-2-yl)-2-(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-81-6P, 3-(2-Amino-5-methyl-1,3-thiazol-4-yl)-2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-83-8P, 3-(2-Amino-4-methyl-1,3-thiazol-5-yl)-2-[(6-chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-85-0P, 3-(2-Amino-4-methyl-1,3-thiazol-5-yl)-2-[(5-chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-87-2P, 3-(2-Amino-5-methyl-1,3-thiazol-4-yl)-2-[(5-chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-89-4P, tert-Butyl [4-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-methylthiazol-2-yl]carbamate 482584-90-7P, 3-(2-Amino-5-methyl-1,3-thiazol-4-yl)-2-(benzothien-3-ylmethyl)-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-91-8P, N-[4-[2-(Benzothien-3-ylmethyl)-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-methyl-1,3-thiazol-2-yl]acetamide 482584-93-0P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-((1Z)-2,2,2-trifluoro-N-hydroxyethanimidoyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-95-2P, 2-(Benzothien-3-ylmethyl)-7-isobutyl-5-methyl-3-(1-methyl-1H-pyrrol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-96-3P, 5-Methyl-2-[(naphth-1-yl)methyl]-3-(4-pyridinyl)-7-[[[(trifluoromethyl)sulfinyl]methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-97-4P, 5-Methyl-2-[(naphth-1-yl)methyl]-3-(4-pyridinyl)-7-[[[(trifluoromethyl)sulfonyl]methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482584-99-6P, 5-Methyl-7-[(methylsulfinyl)methyl]-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-2H-

pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-03-5P,
 5-Methyl-2-[(naphth-1-yl)methyl]-7-[(phenylsulfinyl)methyl]-3-(pyridin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-05-7P
 , 2-[5-Methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-3-(4-pyridinyl)-2,4,5,6-tetrahydro-7H-pyrazolo[3,4-d]pyrimidin-7-yl]butanenitrile
 482585-06-8P, 2-(1-Benzothiophen-3-ylmethyl)-3-(2-fluorophenyl)-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione
 482585-07-9P, 3-(3-Furyl)-7-isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione
 482585-08-0P, 2-(2,3-Dichlorobenzyl)-3-(3-furyl)-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-09-1P
 , 2-(Benzothien-3-ylmethyl)-3-(3-furyl)-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-10-4P,
 2-(3-Bromobenzyl)-7-isobutyl-5-methyl-3-(pyridin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-11-5P, 3-[(7-Isobutyl-5-methyl-4,6-dioxo-3-(pyridin-4-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]benzonitrile 482585-12-6P,
 2-(3-Iodobenzyl)-7-isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-13-7P,
 7-Allyl-5-methyl-2-[(naphth-1-yl)methyl]-3-(4-pyridinyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-15-9P, 7-[2-(Dimethylamino)ethyl]-5-methyl-2-[(naphth-1-yl)methyl]-3-(4-pyridinyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-16-0P,
 3-[7-(2-Chlorobenzyl)-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]benzoic acid
 482585-17-1P, 3-[7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methylbenzamide 482585-38-6P, 5-Methyl-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-7-(2,2,2-trifluoroethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione trifluoroacetate (1:1) 482585-40-0P,
 5-Methyl-3-(1-methyl-1H-imidazol-2-yl)-2-[(naphth-1-yl)methyl]-7-(2,2,2-trifluoroethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-41-1P, 7-(3-Fluoropropyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-[(naphth-1-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-42-2P, 2-(Benzothien-3-ylmethyl)-7-(3-fluoropropyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-43-3P, 2-(Benzothien-3-ylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-propyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-44-4P, 2-(Benzothien-3-ylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2,2,2-trifluoroethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-45-5P,
 2-(Benzothien-3-ylmethyl)-5-methyl-3-(pyridin-4-yl)-7-(2,2,2-trifluoroethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-46-6P, 5-Methyl-3-(1-methyl-1H-imidazol-2-yl)-2-(1-naphthalenylmethyl)-7-propyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-54-6P, N-(tert-Butyl)-2-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazole-4-sulfonamide 482585-55-7P
 , 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-56-8P, 7-Isobutyl-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-2-[(naphth-1-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-57-9P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-3-(1,3-dimethyl-2-thioxo-2,3-dihydro-1H-imidazol-4-yl)-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-58-0P, 3-[2-[(5-Fluoro-3a,7a-dihydro-1-benzothien-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]benzenesulfonamide 482585-59-1P, 3-[7-Isobutyl-5-methyl-2-[(5-methyl-3a,7a-dihydro-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-


d]pyrimidin-3-yl]benzenesulfonamide 482585-60-4P,
 3-[2-[(5-Chloro-3a,7a-dihydro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]benzenesulfonamide 482585-61-5P, 2-[(5-Fluorobenzothien-3-yl)methyl]-7-isobutyl-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-62-6P,
 7-Isobutyl-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-2-[(5-methyl-1H-indol-3-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-63-7P, 2-(1-Benzothien-3-ylmethyl)-7-isobutyl-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-64-8P, 3-(1,3-Dimethyl-2-thioxo-2,3-dihydro-1H-imidazol-4-yl)-7-isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-65-9P, 2-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazole-4-sulfonamide 482585-66-0P, 2-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazole-4-sulfonamide 482585-67-1P,
 2-[7-(Cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazole-4-sulfonamide 482585-68-2P, 2-[2-[(5-Chloro-1-methylsulfonfyl)-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazole-4-sulfonamide 482585-69-3P, 5-[2-[(6-Chloroquinolin-4-yl)methyl]-5-methyl-4,6-dioxo-7-propyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-sulfonamide 482585-77-3P,
 2-[7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-imidazole-4-sulfonamide 482585-78-4P, 3-[7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methylbenzenesulfonamide 482585-83-1P, N-(Aminocarbonyl)-3-[7-isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]benzenesulfonamide 482585-86-4P,
 7-(Cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-2-[(5-methyl-1H-indol-3-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione trifluoroacetate (1:1) 482585-89-7P, 2-[(6-Chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione bis(trifluoroacetate) 482586-16-3P, 2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-17-4P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-3-(1-methyl-1H-imidazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-18-5P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-19-6P,
 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-sulfonamide 482586-20-9P, 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-sulfonamide 482586-21-0P,
 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-3-[1-methyl-4-(methylsulfonfyl)-1H-imidazol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-22-1P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfonfyl)-1H-imidazol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-23-2P,
 5-[2-[(6-Chloroquinolin-4-yl)methyl]-5-methyl-4,6-dioxo-7-propyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-sulfonamide 482586-24-3P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-

pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-sulfonamide
 482586-25-4P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-sulfonamide 482586-26-5P,
 5-[7-(Cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-sulfonamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antibacterial agent; preparation of pyrazolo[3,4-d]pyrimidine H. pylori antibacterial agents by cyclocondensation of pyrimidinylhydrazones with aldehydes)


RN 482583-54-0 CAPLUS

CN Acetamide, N-[4-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]- (CA INDEX NAME)




RN 482583-56-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-(2-methylpropyl)-3-(3-methyl-2-thienyl)-2-(1-naphthalenylmethyl)- (CA INDEX NAME)




RN 482583-57-3 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)





RN 482583-59-5 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-[(2-methylphenyl)methyl]-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482583-63-1 CAPLUS
 CN Benzoic acid, 3-[7-[(3,5-dimethyl-4-isoxazolyl)methyl]-4,5,6,7-tetrahydro-5-methyl-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)

PAGE 1-A






RN 482583-64-2 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(2-methylpropyl)-5-[2-(4-morpholinyl)ethyl]-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482583-69-7 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 1-methyl-5-[4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-, methyl ester (CA INDEX NAME)




RN 482583-72-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-(dimethylamino)ethyl]-1-methyl- (CA INDEX NAME)




RN 482583-76-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(1H-tetrazol-5-yl)-1H-pyrrol-2-yl]- (9CI) (CA INDEX NAME)




RN 482583-77-7 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-, methyl ester (CA INDEX NAME)




RN 482583-78-8 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-, methyl ester (CA INDEX NAME)




RN 482583-79-9 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 2-[2-(benzo[b]thien-3-ylmethyl)-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-, methyl ester (CA INDEX NAME)




RN 482583-80-2 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 1-methyl-5-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-, methyl ester (CA INDEX NAME)




RN 482583-81-3 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(5-chloro-2-methyl-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-, methyl ester (CA INDEX NAME)




RN 482583-82-4 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-, methyl ester (CA INDEX NAME)




RN 482583-83-5 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(5-fluoro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-, methyl ester (CA INDEX NAME)




RN 482583-84-6 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(5-cyano-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-, methyl ester (CA INDEX NAME)




RN 482583-85-7 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[7-(cyclopropylmethyl)-2-[(5-ethyl-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-, methyl ester (CA INDEX NAME)




RN 482583-91-5 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(5-chloro-1H-indazol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482583-92-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482583-93-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-cyclopropyl-5-[7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482583-94-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl- (CA INDEX NAME)




RN 482583-95-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482583-97-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl- (CA INDEX NAME)




RN 482583-98-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482583-99-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-(dimethylamino)ethyl]-1-methyl- (CA INDEX NAME)



RN 482584-00-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-cyclopropyl-1-methyl- (CA INDEX NAME)



RN 482584-01-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 482584-03-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 482584-04-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-(2-aminoethyl)-5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482584-05-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 482584-06-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[3-(1H-imidazol-1-yl)propyl]-1-methyl- (CA INDEX NAME)




RN 482584-07-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-(2-hydroxyethyl)-1-methyl- (CA INDEX NAME)




RN 482584-08-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 482584-09-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-[2-(methylsulfonyl)ethyl]- (CA INDEX NAME)




RN 482584-10-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl- (CA INDEX NAME)




RN 482584-11-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-(2-methoxyethyl)-1-methyl- (CA INDEX NAME)




RN 482584-12-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 482584-13-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-[2-[(1-methylethyl)amino]ethyl]- (CA INDEX NAME)




RN 482584-14-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



RN 482584-15-6 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-cyclopropyl-1-methyl- (CA INDEX NAME)



RN 482584-16-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-cyclopropyl-1-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 482584-17-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 482584-18-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-cyclopropyl-1-methyl-5-[4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482584-19-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-methoxy-1-methyl-5-[4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482584-20-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N,1-dimethyl-5-[4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482584-21-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indazol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482584-22-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indazol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-cyclopropyl-1-methyl- (CA INDEX NAME)




RN 482584-23-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-N-1H-1,2,4-triazol-3-yl- (9CI) (CA INDEX NAME)




RN 482584-24-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-cyclopropyl-1-methyl- (CA INDEX NAME)




RN 482584-25-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-methoxy-1-methyl- (CA INDEX NAME)




RN 482584-26-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482584-27-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 2-[2-(benzo[b]thien-3-ylmethyl)-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-(dimethylamino)ethyl]-1-methyl- (CA INDEX NAME)




RN 482584-28-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-(benzo[b]thien-3-ylmethyl)-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482584-29-2 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[2-(dimethylamino)ethyl]-1-methyl-5-[4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482584-30-5 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-, 2-(dimethylamino)ethyl ester (CA INDEX NAME)



RN 482584-31-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-[2-(dimethylamino)ethyl]-1-methyl- (CA INDEX NAME)




RN 482584-32-7 CAPLUS
 CN Piperazine, 1-[15-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 482584-33-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,N,1-trimethyl- (CA INDEX NAME)




RN 482584-34-9 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482584-35-0 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482584-36-1 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 1-methyl-5-[4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482584-37-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-acetyl-1-methyl-1H-pyrrol-2-yl)-2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl- (CA INDEX NAME)




RN 482584-38-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-acetyl-1-methyl-1H-pyrrol-2-yl)-2-[(6-chloro-4-quinoliny)methyl]-7-(cyclopropylmethyl)-5-methyl- (CA INDEX NAME)




RN 482584-41-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(2,2-dimethylpropyl)-5-methyl-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482584-42-9 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[2-[(5-chloro-1H-indazol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



RN 482584-43-0 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482584-44-1 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-(1-methyl-1H-

imidazol-2-yl)-7-(2-methylpropyl)-2-[(5-nitro-1H-indol-3-yl)methyl]- (CA INDEX NAME)




RN 482584-45-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-2-methyl-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482584-46-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482584-47-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)-2-(1-naphthalenylmethyl)- (CA INDEX NAME)




RN 482584-48-5 CAPLUS

CN 1H-Pyrazolo-3-carbonitrile, 1-methyl-5-[4,5,6,7-tetrahydro-5-methyl-2-[(2-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482584-49-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482584-50-9 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-methyl-7-(2-methylpropyl)-3-(3-methyl-2-thienyl)- (CA INDEX NAME)




RN 482584-51-0 CAPLUS
 CN 1H-Indole-5-carbonitrile, 3-[[4,5,6,7-tetrahydro-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]- (CA INDEX NAME)



RN 482584-52-1 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-methoxy-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482584-53-2 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-[(4-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482584-54-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(2-thienyl)- (CA INDEX NAME)




RN 482584-55-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-methyl-7-(2-methylpropyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482584-57-6 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)-5-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 482584-58-7 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-(2-hydroxyethyl)-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482584-59-8 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)-5-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 482584-60-1 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)-5-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 482584-61-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-7-(3-methylbutyl)-3-(1-methyl-1H-imidazol-2-yl)- (CA INDEX NAME)




RN 482584-62-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclobutylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)- (CA INDEX NAME)




RN 482584-64-5 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-7-[(3,5-dimethyl-4-isoxazolyl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)- (CA INDEX NAME)



RN 482584-65-6 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-propyl- (CA INDEX NAME)




RN 482584-66-7 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 482584-67-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-[(3,5-dimethyl-4-isoxazolyl)methyl]-5-methyl-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 482584-68-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-[(4-hydroxyphenyl)methyl]-5-methyl-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482584-69-0 CAPLUS

CN Benzoic acid, 3-[[2,4,5,6-tetrahydro-5-methyl-2-(1-naphthalenylmethyl)-4,6-dioxo-3-(4-pyridinyl)-7H-pyrazolo[3,4-d]pyrimidin-7-yl)methyl]- (CA INDEX NAME)




RN 482584-71-4 CAPLUS

CN Benzamide, 3-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482584-72-5 CAPLUS

CN Benzoic acid, 3-[4,5,6,7-tetrahydro-5-methyl-7-(3-methylbutyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482584-74-7 CAPLUS

CN Benzoic acid, 3-[7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482584-75-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-amino-1-methyl-1H-imidazol-2-yl)-2-(benzo[b]thien-3-ylmethyl)-5-methyl-7-(2-methylpropyl)-(CA INDEX NAME)




RN 482584-77-0 CAPLUS

CN Acetamide, N-[2-[2-(benzo[b]thien-3-ylmethyl)-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 482584-79-2 CAPLUS

CN Carbamic acid, [2-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-imidazol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 482584-80-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-amino-1-methyl-1H-imidazol-2-yl)-2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-5-methyl- (CA INDEX NAME)




RN 482584-81-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(2-amino-5-methyl-4-thiazolyl)-2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-5-methyl- (CA INDEX NAME)




RN 482584-83-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(2-amino-4-methyl-5-thiazolyl)-2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-5-methyl- (CA INDEX NAME)




RN 482584-85-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(2-amino-4-methyl-5-thiazolyl)-2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-7-(2-methylpropyl)-(CA INDEX NAME)




RN 482584-87-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(2-amino-5-methyl-4-thiazolyl)-2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-7-(2-methylpropyl)-(CA INDEX NAME)




RN 482584-89-4 CAPLUS

CN Carbamic acid, [4-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-methyl-2-thiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 482584-90-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(2-amino-5-methyl-4-thiazolyl)-2-(benzo[b]thien-3-ylmethyl)-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482584-91-8 CAPLUS

CN Acetamide, N-[4-[2-(benzo[b]thien-3-ylmethyl)-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-methyl-2-thiazolyl]- (CA INDEX NAME)




RN 482584-93-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-[2,2,2-trifluoro-1-(hydroxyimino)ethyl]-1H-pyrrol-2-yl]- (CA INDEX NAME)




RN 482584-95-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-methyl-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)- (CA INDEX NAME)




RN 482584-96-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)-7-[[1-(trifluoromethyl)sulfinyl]methyl]- (CA INDEX NAME)




RN 482584-97-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-2-[(1-naphthalenyl)methyl]-3-(4-pyridinyl)-7-[[(trifluoromethyl)sulfonyl]methyl]- (CA INDEX NAME)




RN 482584-99-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-[(methylsulfinyl)methyl]-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482585-03-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-2-(1-naphthalenylmethyl)-7-[(phenylsulfinyl)methyl]-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482585-05-7 CAPLUS

CN 7H-Pyrazolo[3,4-d]pyrimidine-7-acetonitrile, α -ethyl-2,4,5,6-tetrahydro-5-methyl-2-(1-naphthalenylmethyl)-4,6-dioxo-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482585-06-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-3-(2-fluorophenyl)-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482585-07-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(3-furanyl)-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)- (CA INDEX NAME)




RN 482585-08-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(2,3-dichlorophenyl)methyl]-3-(3-furanyl)-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482585-09-1 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-3-(3-furanyl)-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482585-10-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(3-bromophenyl)methyl]-5-methyl-7-(2-methylpropyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482585-11-5 CAPLUS

CN Benzonitrile, 3-[[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-3-(4-pyridinyl)-2H-pyrazolo[3,4-d]pyrimidin-2-yl]methyl]- (CA INDEX NAME)




RN 482585-12-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(3-iodophenyl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482585-13-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-2-(1-naphthalenylmethyl)-7-(2-propenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 482585-15-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-[2-(dimethylamino)ethyl]-5-methyl-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482585-16-0 CAPLUS

CN Benzoic acid, 3-[7-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro-5-methyl-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)



RN 482585-17-1 CAPLUS

CN Benzamide, N-methyl-3-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482585-38-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-2-[(1-naphthalenylmethyl)-3-(4-pyridinyl)-7-(2,2,2-trifluoroethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 482585-37-5

CMF C24 H18 F3 N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 482585-40-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-(1-naphthalenylmethyl)-7-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 482585-41-1 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(3-fluoropropyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-(1-naphthalenylmethyl)- (CA INDEX NAME)




RN 482585-42-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-7-(3-fluoropropyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)- (CA INDEX NAME)




RN 482585-43-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-propyl- (CA INDEX NAME)




RN 482585-44-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 482585-45-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-methyl-3-(4-pyridinyl)-7-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 482585-46-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-(1-naphthalenylmethyl)-7-propyl- (CA INDEX NAME)




RN 482585-54-6 CAPLUS

CN 1H-Imidazole-4-sulfonamide, 2-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N-(1,1-dimethylethyl)-1-methyl- (CA INDEX NAME)




RN 482585-55-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482585-56-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-(1-methyl-1H-imidazol-5-yl)-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)- (CA INDEX NAME)




RN 482585-57-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-3-(2,3-dihydro-1,3-dimethyl-2-thioxo-1H-imidazol-4-yl)-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482585-58-0 CAPLUS

CN Benzenesulfonamide, 3-[2-[(5-fluoro-3a,7a-dihydrobenzo[b]thien-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482585-59-1 CAPLUS

CN Benzenesulfonamide, 3-[2-[(3a,7a-dihydro-5-methyl-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482585-60-4 CAPLUS

CN Benzenesulfonamide, 3-[2-[(5-chloro-3a,7a-dihydro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482585-61-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-fluorobenzo[b]thien-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482585-62-6 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-(1-methyl-1H-imidazol-5-yl)-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482585-63-7 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482585-64-8 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(2,3-dihydro-1,3-dimethyl-2-thioxo-1H-imidazol-4-yl)-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)- (CA INDEX NAME)




RN 482585-65-9 CAPLUS
 CN 1H-Imidazole-4-sulfonamide, 2-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482585-66-0 CAPLUS

CN 1H-imidazole-4-sulfonamide, 2-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482585-67-1 CAPLUS

CN 1H-imidazole-4-sulfonamide, 2-[7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482585-68-2 CAPLUS

CN 1H-Imidazole-4-sulfonamide, 2-[2-[[5-chloro-1-(methylsulfonyl)-1H-indol-3-yl]methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482585-69-3 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-7-propyl-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482585-77-3 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N,1-dimethyl-2-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482585-78-4 CAPLUS

CN Benzenesulfonamide, N-methyl-3-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)



RN 482585-83-1 CAPLUS

CN Benzenesulfonamide, N-(aminocarbonyl)-3-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482585-86-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-5-methyl-3-[(1-methyl-1H-imidazol-5-yl)-2-[(5-methyl-1H-indol-3-yl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 482585-85-3

CMF C24 H25 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 482585-89-7 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 482585-88-6

CMF C24 H22 Cl N7 O2

PAGE 1-A



PAGE 2-A



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 482586-16-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-5-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-17-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-3-(1-methyl-1H-imidazol-5-yl)-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482586-18-5 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-5-yl)- (CA INDEX NAME)



RN 482586-19-6 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-


d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482586-20-9 CAPLUS


CN 1H-Pyrrole-3-sulfonamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)

PAGE 1-A






RN 482586-21-0 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-[1-methyl-4-(methylsulfonyl)-1H-imidazol-2-yl]-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-22-1 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfonyl)-1H-imidazol-2-yl]- (CA INDEX NAME)




RN 482586-23-2 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-7-propyl-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482586-24-3 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482586-25-4 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)



RN 482586-26-5 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)



IT 482586-27-6P, 5-[7-Isobutyl-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-sulfonamide 482586-28-7P, 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-sulfonamide 482586-29-8P, 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-sulfonamide 482586-30-1P, 5-[7-(Cyclopropylmethyl)-2-[(5-fluorobenzothien-3-yl)methyl]-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-sulfonamide 482586-31-2P, 5-[2-[(5-Fluorobenzothien-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-sulfonamide 482586-32-3P, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-5-methyl-4,6-dioxo-7-propyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl-1H-pyrrole-3-sulfonamide 482586-33-4P, N-[[5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-

pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrol-3-yl)sulfonyl]glycine
 482586-34-5P, N-[5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-
 (cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-
 d]pyrimidin-3-yl]-1-methyl-1H-pyrrol-3-yl)sulfonyl]glycine
 482586-35-6P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-3-(1-
 methyl-1H-imidazol-5-yl)-5-(2-(morpholin-4-yl)ethyl)-2H-pyrazolo[3,4-
 d]pyrimidine-4,6(5H,7H)-dione 482586-36-7P, 2-[(5-
 Fluorobenzothien-3-yl)methyl]-7-isobutyl-3-(pyridin-4-yl)-2H-pyrazolo[3,4-
 d]pyrimidine-4,6(5H,7H)-dione 482586-37-8P, 2-[(5-
 Chlorobenzothien-3-yl)methyl]-7-isobutyl-3-(pyridin-4-yl)-2H-pyrazolo[3,4-
 d]pyrimidine-4,6(5H,7H)-dione 482586-38-9P, 2-[(5-
 Chlorobenzothien-3-yl)methyl]-7-isobutyl-3-(1-methyl-1H-imidazol-2-yl)-2H-
 pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-39-0P, 2-[(5-
 Fluorobenzothien-3-yl)methyl]-7-isobutyl-3-(1-methyl-1H-imidazol-2-
 yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-40-3P, 2-[(5-
 Fluorobenzothien-3-yl)methyl]-7-isobutyl-5-methyl-3-(1-methyl-1H-
 pyrrol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione
 482586-41-4P, 2-[(5-Fluorobenzothien-3-yl)methyl]-7-isobutyl-5-
 methyl-3-(pyridin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione
 482586-42-5P, N-[5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-
 5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-
 yl]pyridin-2-yl]acetamide 482586-43-6P, N-[5-[2-[(5-
 Fluorobenzothien-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-
 tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]pyridin-2-yl]acetamide
 482586-44-7P, 2-[(5-Fluorobenzothien-3-yl)methyl]-7-isobutyl-5-
 methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-
 4,6(5H,7H)-dione 482586-45-8P, 2-[(5-Chloro-1H-indol-3-
 yl)methyl]-7-isobutyl-5-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)-2H-
 pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-46-9P, 7-
 Isobutyl-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-3-(4-methyl-4H-
 1,2,4-triazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione
 482586-47-0P, 7-(Cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-
 3-yl)methyl]-3-(4-methyl-4H-1,2,4-triazol-3-yl)-2H-pyrazolo[3,4-
 d]pyrimidine-4,6(5H,7H)-dione 482586-48-1P, 2-[(5-Chloro-1H-
 indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(4-methyl-4H-1,2,4-
 triazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione
 482586-49-2P, 2-[(5-Chloro-1H-indazol-3-yl)methyl]-7-isobutyl-5-
 methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-
 4,6(5H,7H)-dione 482586-50-5P, 2-[(5-Chloro-1H-indazol-3-
 yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-
 pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-51-6P, 2-[(5-
 Fluorobenzothien-3-yl)methyl]-7-isobutyl-5-methyl-3-(4-methyl-4H-
 1,2,4-triazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione
 482586-52-7P, 2-[(5-Chloro-1H-indazol-3-yl)methyl]-7-isobutyl-5-
 methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidine-
 4,6(5H,7H)-dione 482586-53-8P, 2-[(6-Chloroquinolin-4-yl)methyl]-
 7-isobutyl-5-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)-2H-pyrazolo[3,4-
 d]pyrimidine-4,6(5H,7H)-dione 482586-54-9P, 7-
 (Cyclopropylmethyl)-2-[(5-fluorobenzothien-3-yl)methyl]-5-methyl-3-(4-
 methyl-4H-1,2,4-triazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-
 dione 482586-55-0P, 2-[(5-Chloro-1H-indazol-3-yl)methyl]-7-
 (cyclopropylmethyl)-5-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)-2H-
 pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-56-1P, [6-
 Chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(4-methyl-
 4H-1,2,4-triazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione
 482586-57-2P, 3-(4-Bromo-1-methyl-1H-pyrrol-2-yl)-2-[(5-chloro-1H-
 indol-3-yl)methyl]-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-
 4,6(5H,7H)-dione 482586-58-3P, 2-[(5-Chloro-1H-indol-3-
 yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfinyl)-

1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione
 482586-59-4P, 7-(Cyclopropylmethyl)-2-[(5-fluorobenzothien-3-yl)methyl]-5-methyl-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-60-7P,
 7-(Cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-61-8P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-62-9P,
 7-Isobutyl-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-63-0P, 2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-64-1P, 2-[(6-Chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-65-2P, 7-(Cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-3-[1-methyl-4-(methylthio)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-66-3P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-67-4P, 7-(Cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-3-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-68-5P,
 7-(Cyclopropylmethyl)-2-[(5-fluorobenzothien-3-yl)methyl]-5-methyl-3-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-69-6P, 2-[(6-Chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-70-7P, 2-[(5-chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-71-0P, 3-(4-Acetyl-1-methyl-1H-pyrrol-2-yl)-2-[(5-chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-72-1P, 1-[5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrol-3-yl]ethylidenecyanamide 482586-73-2P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-3-(1-methyl-4-propionyl-1H-pyrrol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-74-3P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-3-[4-[(1E)-N-hydroxyethanimidoyl]-1-methyl-1H-pyrrol-2-yl]-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-75-4P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-3-[4-(1-hydroxyethyl)-1-methyl-1H-pyrrol-2-yl]-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-76-5P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-3-[4-[(1E)-N-methoxyethanimidoyl]-1-methyl-1H-pyrrol-2-yl]-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-77-6P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-3-(4-isobutyl-1-methyl-1H-imidazol-2-yl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-79-8P, 3-(4-Acetyl-1-methyl-1H-imidazol-2-yl)-2-[(5-chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-81-2P, 3-(4-Acetyl-1-methyl-1H-pyrrol-2-yl)-2-[(6-chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-82-3P, 2-(Benzothien-3-ylmethyl)-5-(2-hydroxyethyl)-7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-83-4P, 2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-3-(1-methyl-1H-pyrrol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-84-5P, 2-(Benzothien-3-ylmethyl)-7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-5-(pyridin-2-ylmethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-85-6P, 2-[(6-Fluoroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-3-(1-methyl-4-propionyl-1H-pyrrol-2-yl)-2H-

pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-87-8P,
 2-(Benzothien-3-ylmethyl)-7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-5-(2-
 (morpholin-4-yl)ethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione
 482586-88-9P, 3-(4-Acetyl-1-methyl-1H-pyrrol-2-yl)-2-[(6-
 fluoroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-2H-pyrazolo[3,4-
 d]pyrimidine-4,6(5H,7H)-dione 482586-89-0P, 2-(Benzothien-3-
 ylmethyl)-7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-5-(pyridin-3-ylmethyl)-2H-
 pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-90-3P,
 2-(Benzothien-3-ylmethyl)-5-[2-[(2S)-2-[(dimethylamino)methyl]morpholin-4-
 yl)ethyl]-7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-2H-pyrazolo[3,4-
 d]pyrimidine-4,6(5H,7H)-dione 482586-91-4P, 2-(Benzothien-3-
 ylmethyl)-7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-5-(2-(piperidin-1-
 yl)ethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione
 482586-92-5P, 2-(Benzothien-3-ylmethyl)-5-[2-(dimethylamino)ethyl]-
 7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-
 4,6(5H,7H)-dione 482586-93-6P, 2-(Benzothien-3-ylmethyl)-7-
 isobutyl-5-[(1-methylpiperidin-3-yl)methyl]-3-(1-methyl-1H-pyrrol-2-yl)-2H-
 pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-94-7P,
 2-[(5-Chloro-1H-indol-3-yl)methyl]-3-[4-[(dimethylamino)acetyl]-1-methyl-
 1H-pyrrol-2-yl]-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-
 4,6(5H,7H)-dione 482586-95-8P, 2-(Benzothien-3-ylmethyl)-7-
 isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-
 d]pyrimidine-4,6(5H,7H)-dione 482586-96-9P, 2-[(6-Chloroquinolin-
 4-yl)methyl]-7-isobutyl-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-
 pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482586-97-0P,
 2-[(6-Fluoroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-3-(1-methyl-1H-
 imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione
 482586-98-1P, 2-(Benzothien-3-ylmethyl)-5-[2-(1H-imidazol-1-
 yl)ethyl]-7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-2H-pyrazolo[3,4-
 d]pyrimidine-4,6(5H,7H)-dione 482587-00-8P, 2-[(5-Chloro-1H-
 indol-3-yl)methyl]-3-(1-ethyl-1H-pyrrol-2-yl)-7-isobutyl-5-methyl-2H-
 pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-01-9P,
 N-[2-[(2-1-Benzothien-3-ylmethyl)-7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-
 4,6-dioxo-2,4,6,7-tetrahydro-5H-pyrazolo[3,4-d]pyrimidin-5-
 yl]ethyl]guanidine 482587-02-0P, 3-(4-Acetyl-1-methyl-1H-pyrrol-
 2-yl)-7-isobutyl-5-methyl-2-[(6-(trifluoromethyl)quinolin-4-yl)methyl]-2H-
 pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-04-2P,
 2-(Benzothien-3-ylmethyl)-7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-5-[2-(1H-
 pyrazol-1-yl)ethyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione
 482587-05-3P, 7-Isobutyl-5-methyl-3-(1-methyl-4-propionyl-1H-
 pyrrol-2-yl)-2-[(6-(trifluoromethyl)quinolin-4-yl)methyl]-2H-pyrazolo[3,4-
 d]pyrimidine-4,6(5H,7H)-dione 482587-06-4P, 7-
 (Cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-[(5-
 (trifluoromethyl)-1H-indol-3-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-
 4,6(5H,7H)-dione 482587-07-5P, 7-(Cyclopropylmethyl)-5-methyl-3-
 (1-methyl-1H-pyrrol-2-yl)-2-[(5-(trifluoromethyl)-1H-indol-3-yl)methyl]-2H-
 pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-09-7P,
 2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-3-(4-methyl-4H-1,2,4-triazol-
 3-yl)-5-(2-(morpholin-4-yl)ethyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-
 dione 482587-10-0P, [2-[(6-Chloroquinolin-4-yl)methyl]-7-
 isobutyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)-4,6-dioxo-2,4,6,7-tetrahydro-
 5H-pyrazolo[3,4-d]pyrimidin-5-yl]acetoneitrile 482587-14-4P,
 7-(Cyclopropylmethyl)-3-[(3R)-3-hydroxypyrrolidin-1-yl]-5-methyl-2-
 [(naphth-1-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione
 482587-15-5P, 2-[(5-Chlorobenzothien-3-yl)methyl]-7-isobutyl-5-
 methyl-3-(piperazin-1-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione
 482587-16-6P, 7-Isobutyl-5-methyl-2-[(naphth-1-yl)methyl]-3-
 (piperazin-1-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione
 482587-17-7P, 2-[(5-Chlorobenzothien-3-yl)methyl]-7-isobutyl-5-


methyl-3-(4-methylpiperazin-1-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-19-9P, 2-[(5-Chlorobenzothien-3-yl)methyl]-7-isobutyl-5-methyl-3-(piperidin-1-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-20-2P, 2-[(5-Chlorobenzothien-3-yl)methyl]-7-isobutyl-5-methyl-3-(morpholin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-21-3P, 2-[(6-Chloroquinolin-4-yl)methyl]-3-(3-hydroxypyrrolidin-1-yl)-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-22-4P, 2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-5-methyl-3-(piperazin-1-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-23-5P, 7-(Cyclopropylmethyl)-5-methyl-2-(naphth-1-ylmethyl)-3-(piperazin-1-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-24-6P, 4-[7-(Cyclopropylmethyl)-5-methyl-2-(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,N-dimethylpiperazine-1-sulfonamide 482587-25-7P, 7-(Cyclopropylmethyl)-3-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methyl-2-(naphth-1-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-26-8P, 7-(Cyclopropylmethyl)-3-(3-hydroxypiperidin-1-yl)-5-methyl-2-[(naphth-1-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-27-9P, 3-[(3S)-3-Aminopyrrolidin-1-yl]-7-(cyclopropylmethyl)-5-methyl-2-[(naphth-1-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-28-0P, 3-[(3R)-3-Aminopyrrolidin-1-yl]-7-(cyclopropylmethyl)-5-methyl-2-[(naphth-1-yl)methyl]-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-29-1P, 2-[(5-Chloro-1H-indol-3-yl)methyl]-7-isobutyl-5-methyl-3-(3-Methylisoxazol-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482587-30-4P, 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carbonitrile 482587-31-5P, 2-[(6-Chloroquinolin-4-yl)methyl]-7-isobutyl-3-(1-methyl-1H-pyrrol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antibacterial agent; preparation of pyrazolo[3,4-d]pyrimidine H. pylori antibacterial agents by cyclocondensation of pyrimidinylhydrazones with aldehydes)

RN 482586-27-6 CAPLUS


CN 1H-Pyrrole-3-sulfonamide, N,1-dimethyl-5-[4,5,6,7-tetrahydro-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




RN 482586-28-7 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 482586-29-8 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482586-30-1 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[7-(cyclopropylmethyl)-2-[(5-fluorobenzo[b]thien-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482586-31-2 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[2-[(5-fluorobenzo[b]thien-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)




RN 482586-32-3 CAPLUS

CN 1H-Pyrrole-3-sulfonamide, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-7-propyl-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,1-dimethyl- (CA INDEX NAME)



RN 482586-33-4 CAPLUS


CN Glycine, N-[15-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrol-3-yl]sulfonyl- (CA INDEX NAME)




RN 482586-34-5 CAPLUS

CN Glycine, N-[(5-[2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrol-3-yl)sulfonyl]- (CA INDEX NAME)


PAGE 1-A






RN 482586-35-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-3-(1-methyl-1H-imidazol-5-yl)-7-(2-methylpropyl)-5-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 482586-36-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-fluorobenzo[b]thien-3-yl)methyl]-7-(2-methylpropyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482586-37-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chlorobenzo[b]thien-3-yl)methyl]-7-(2-methylpropyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482586-38-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chlorobenzo[b]thien-3-yl)methyl]-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-39-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-fluorobenzo[b]thien-3-yl)methyl]-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-40-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-fluorobenzo[b]thien-3-yl)methyl]-5-methyl-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)- (CA INDEX NAME)




RN 482586-41-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-fluorobenzo[b]thien-3-yl)methyl]-5-methyl-7-(2-methylpropyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482586-42-5 CAPLUS

CN Acetamide, N-[5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-pyridinyl]- (CA INDEX NAME)




RN 482586-43-6 CAPLUS


CN Acetamide, N-[5-[2-[(5-fluorobenzo[b]thien-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-pyridinyl]- (CA INDEX NAME)




RN 482586-44-7 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-fluorobenzo[b]thien-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482586-45-8 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-7-(2-methylpropyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)- (CA INDEX NAME)




RN 482586-46-9 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-7-(2-methylpropyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)- (CA INDEX NAME)




RN 482586-47-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-3-(4-methyl-4H-1,2,4-triazol-3-yl)- (CA INDEX NAME)




RN 482586-48-1 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)- (CA INDEX NAME)




RN 482586-49-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indazol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-50-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indazol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)- (CA INDEX NAME)




RN 482586-51-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-fluorobenzo[b]thien-3-yl)methyl]-5-methyl-7-(2-methylpropyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)- (CA INDEX NAME)




RN 482586-52-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indazol-3-yl)methyl]-5-methyl-7-(2-methylpropyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)- (CA INDEX NAME)




RN 482586-53-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-5-methyl-7-(2-methylpropyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)- (CA INDEX NAME)




RN 482586-54-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-2-[(5-fluorobenzo[b]thien-3-yl)methyl]-5-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)- (CA INDEX NAME)




RN 482586-55-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indazol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)- (CA INDEX NAME)




RN 482586-56-1 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)- (CA INDEX NAME)




RN 482586-57-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-bromo-1-methyl-1H-pyrrol-2-yl)-2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-58-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]- (CA INDEX NAME)




RN 482586-59-4 CAPLUS

2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-2-[(5-fluorobenzo[b]thien-3-yl)methyl]-5-methyl-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]- (CA INDEX NAME)




RN 482586-60-7 CAPLUS

2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]- (CA INDEX NAME)




RN 482586-61-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-62-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-3-[1-methyl-4-(methylsulfinyl)-1H-pyrrol-2-yl]-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482586-63-0 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-5-methyl-3-[1-methyl-4-(methanesulfinyl)-1H-pyrrol-2-yl]-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482586-64-1 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methanesulfinyl)-1H-pyrrol-2-yl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 482586-65-2 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-3-[1-methyl-4-(methylthio)-1H-pyrrol-2-yl]- (CA INDEX NAME)




RN 482586-66-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]- (CA INDEX NAME)




RN 482586-67-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-5-methyl-2-[(5-methyl-1H-indol-3-yl)methyl]-3-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]- (CA INDEX NAME)




RN 482586-68-5 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-2-[(5-fluorobenzo[b]thien-3-yl)methyl]-5-methyl-3-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]- (CA INDEX NAME)




RN 482586-69-6 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-7-(cyclopropylmethyl)-5-methyl-3-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]- (CA INDEX NAME)

PAGE 1-A







RN 482586-71-0 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-acetyl-1-methyl-1H-pyrrol-2-yl)-2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482586-72-1 CAPLUS
 CN Cyanamide, [1-[5-[2-[(5-chloro-1H-indol-3-yl)methyl]-4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrol-3-yl]ethylidene]- (9CI) (CA INDEX NAME)




RN 482586-73-2 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-[1-methyl-4-(1-oxopropyl)-1H-pyrrol-2-yl]-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482586-74-3 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-3-[4-[(1E)-1-(hydroxyimino)ethyl]-1-methyl-1H-pyrrol-2-yl]-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 482586-75-4 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-3-[4-[(1E)-1-(hydroxyethyl)-1-methyl-1H-pyrrol-2-yl]-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482586-76-5 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-3-[4-[(1E)-1-(methoxyimino)ethyl]-1-methyl-1H-pyrrol-2-yl]-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)

Double bond geometry as shown.




RN 482586-77-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-[1-methyl-4-(2-methyl-1-oxopropyl)-1H-imidazol-2-yl]-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-79-8 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-acetyl-1-methyl-1H-imidazol-2-yl)-2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-81-2 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-acetyl-1-methyl-1H-pyrrol-2-yl)-2-[(6-chloro-4-quinolinyl)methyl]-5-methyl-7-(2-methylpropyl)-
 (CA INDEX NAME)



RN 482586-82-3 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-(2-hydroxyethyl)-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)-
 (CA INDEX NAME)




RN 482586-83-4 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-5-methyl-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)-
 (CA INDEX NAME)




RN 482586-84-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)-5-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 482586-85-6 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-fluoro-4-quinolinyl)methyl]-5-methyl-3-[1-methyl-4-(1-oxopropyl)-1H-pyrrol-2-yl]-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482586-87-8 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-

ylmethyl)-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)-5-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 482586-88-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-acetyl-1-methyl-1H-pyrrol-2-yl)-2-[(6-fluoro-4-quinolinyl)methyl]-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482586-89-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)-5-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 482586-90-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-


ylmethyl)-5-[2-[(2S)-2-[(dimethylamino)methyl]-4-morpholinyl]ethyl]-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 482586-91-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)-5-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 482586-92-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-[2-(dimethylamino)ethyl]-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)- (CA INDEX NAME)




RN 482586-93-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-[(1-methyl-3-piperidinyl)methyl]-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)- (CA INDEX NAME)




RN 482586-94-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-3-[4-[(dimethylamino)acetyl]-1-methyl-1H-pyrrol-2-yl]-5-methyl-7-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 482586-95-8 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-96-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-97-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-fluoro-4-quinolinyl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482586-98-1 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-5-[2-(1H-imidazol-1-yl)ethyl]-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)- (CA INDEX NAME)




RN 482587-00-8 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-3-(1-ethyl-1H-pyrrol-2-yl)-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482587-01-9 CAPLUS
 CN Guanidine, [2-[2-(benzo[b]thien-3-ylmethyl)-2,4,6,7-tetrahydro-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)-4,6-dioxo-5H-pyrazolo[3,4-d]pyrimidin-5-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 482587-02-0 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-acetyl-1-methyl-1H-pyrrol-2-yl)-5-methyl-7-(2-methylpropyl)-2-[[6-(trifluoromethyl)-4-quinolinyl]methyl]- (CA INDEX NAME)




RN 482587-04-2 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-(benzo[b]thien-3-ylmethyl)-3-(1-methyl-1H-pyrrol-2-yl)-5-[2-(1H-pyrazol-1-yl)ethyl]- (CA INDEX NAME)




RN 482587-05-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-[1-methyl-4-(1-oxopropyl)-1H-pyrrol-2-yl]-7-(2-methylpropyl)-2-[[6-(trifluoromethyl)-4-quinolinyl]methyl]- (CA INDEX NAME)



RN 482587-06-4 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2-[[5-(trifluoromethyl)-1H-indol-3-yl]methyl]- (CA INDEX NAME)



RN 482587-07-5 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-5-

methyl-3-(1-methyl-1H-pyrrol-2-yl)-2-[[5-(trifluoromethyl)-1H-indol-3-yl]methyl]- (CA INDEX NAME)




RN 482587-09-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-7-(2-methylpropyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)-5-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 482587-10-0 CAPLUS


CN 5H-Pyrazolo[3,4-d]pyrimidine-5-acetonitrile, 2-[(6-chloro-4-quinolinyl)methyl]-2,4,6,7-tetrahydro-7-(2-methylpropyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)-4,6-dioxo- (CA INDEX NAME)



RN 482587-14-4 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-3-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-methyl-2-(1-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 482587-15-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chlorobenzo[b]thien-3-yl)methyl]-5-methyl-7-(2-methylpropyl)-3-(1-piperazinyl)- (CA INDEX NAME)




RN 482587-16-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(1-piperazinyl)- (CA INDEX NAME)




RN 482587-17-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chlorobenzo[b]thien-3-yl)methyl]-5-methyl-3-(4-methyl-1-piperazinyl)-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482587-19-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chlorobenzo[b]thien-3-yl)methyl]-5-methyl-7-(2-methylpropyl)-3-(1-piperidinyl)- (CA INDEX NAME)




RN 482587-20-2 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chlorobenzo[b]thien-3-yl)methyl]-5-methyl-7-(2-methylpropyl)-3-(4-morpholinyl)- (CA INDEX NAME)




RN 482587-21-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinoliny)methyl]-3-(3-hydroxy-1-pyrrolidinyl)-5-methyl-7-(2-methylpropyl)- (CA INDEX NAME)




RN 482587-22-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinoliny)methyl]-5-methyl-7-(2-methylpropyl)-3-(1-piperazinyl)- (CA INDEX NAME)




RN 482587-23-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-5-methyl-2-(1-naphthalenylmethyl)-3-(1-piperazinyl)- (CA INDEX NAME)



RN 482587-24-6 CAPLUS


CN 1-Piperazinesulfonamide, 4-[7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,N-dimethyl- (CA INDEX NAME)



RN 482587-25-7 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-5-methyl-2-(1-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 482587-26-8 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(cyclopropylmethyl)-3-(3-hydroxy-1-piperidinyl)-5-methyl-2-(1-naphthalenylmethyl)- (CA INDEX NAME)



RN 482587-27-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-[(3S)-3-amino-1-pyrrolidinyl]-7-(cyclopropylmethyl)-5-methyl-2-(1-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 482587-28-0 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-[(3R)-3-amino-1-pyrrolidinyl]-7-(cyclopropylmethyl)-5-methyl-2-(1-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 482587-29-1 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-(3-methyl-4-isoxazolyl)-7-(2-methylpropyl)- (CA INDEX NAME)



RN 482587-30-4 CAPLUS
 CN 1H-Pyrazolo-3-carbonitrile, 5-[2-[(6-chloro-4-quinolinyl)methyl]-4,5,6,7-tetrahydro-7-(2-methylpropyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)



RN 482587-31-5 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(6-chloro-4-quinolinyl)methyl]-7-(2-methylpropyl)-3-(1-methyl-1H-pyrrol-2-yl)- (CA INDEX NAME)




IT 482583-62-0P, 5-Methyl-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482583-68-6P, 7-Isobutyl-2-[(naphth-1-yl)methyl]-3-(pyridin-4-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 482585-04-6P, 3-[7-Isobutyl-5-

methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]benzonitrile
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrazolo[3,4-d]pyrimidine H. pylori antibacterial agents by cyclocondensation of pyrimidinylhydrazones with aldehydes)


RN 482583-62-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 482583-68-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-3-(4-pyridinyl)- (CA INDEX NAME)




RN 482585-04-6 CAPLUS

CN Benzonitrile, 3-[4,5,6,7-tetrahydro-5-methyl-7-(2-methylpropyl)-2-(1-naphthalenylmethyl)-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)




IT 482583-96-0, 5-[2-[(5-Chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylic acid
 482584-02-1, 5-[2-[(6-Chloroquinolin-4-yl)methyl]-7-(cyclopropylmethyl)-5-methyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl-1H-pyrrole-3-carboxylic acid
 482584-63-4, 2-[(5-Chloro-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione
 482584-73-6D, 3-[5-Methyl-2-[(naphth-1-yl)methyl]-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl]benzoic acid, resin bound 482584-78-1, 3-(4-Amino-1-methyl-1H-imidazol-2-yl)-2-(benzothien-3-ylmethyl)-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione hydrochloride 482584-92-9, 3-(2-Amino-5-methyl-1,3-thiazol-4-yl)-2-(benzothien-3-ylmethyl)-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione hydrochloride
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrazolo[3,4-d]pyrimidine H. pylori antibacterial agents by cyclocondensation of pyrimidinylhydrazones with aldehydes)
 RN 482583-96-0 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(5-chloro-1H-indol-3-yl)methyl]-7-(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482584-02-1 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[2-[(6-chloro-4-quinolinyl)methyl]-7-

(cyclopropylmethyl)-4,5,6,7-tetrahydro-5-methyl-4,6-dioxo-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-1-methyl- (CA INDEX NAME)




RN 482584-63-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[(5-chloro-1H-indol-3-yl)methyl]-5-methyl-3-(1-methyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 482584-73-6 CAPLUS

CN Benzoic acid, 3-[2,4,5,6-tetrahydro-5-methyl-2-(1-naphthalenylmethyl)-4,6-dioxo-1H-pyrazolo[3,4-d]pyrimidin-3-yl]- (CA INDEX NAME)



RN 482584-78-1 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-amino-1-methyl-1H-imidazol-2-yl)-2-(benzo[b]thien-3-ylmethyl)-5-methyl-7-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 482584-92-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(2-amino-5-methyl-4-thiazolyl)-2-(benzo[b]thien-3-ylmethyl)-5-methyl-7-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

GI



I



II

AB Title compds. I [wherein R1 and R2 = independently H, NH2, or (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, aryl, alkoxy, or heterocyclyl; R3 = (un)substituted monocyclic or bicyclic ring system comprising 0-3 heteroatoms independently selected from N, O, or S; R4 = (un)substituted alkyl or (di)alkylamino, with exceptions; Y = CH2, CHCH3, SO, or SO2; and pharmaceutically acceptable salts thereof] were prepared For example, 6-hydrazino-1-isobutyl-3-methylpyrimidine-2,4-(1H,3H)-dione (4-step preparation given) was condensed with 1-naphthaldehyde in MeOH to give the hydrazone. Cyclocondensation with N-(4-formylphenyl)acetamide in DMF afforded II. Compds. of the invention exhibited glutamate racemase (MurI) activity with IC50 values of < 400 μ M. Thus, I and pharmaceutical compns. containing them are useful in the treatment or prophylaxis of *Helicobacter pylori* (*H. pylori*) infection (no data).

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1983:53834 CAPLUS

DOCUMENT NUMBER: 98:53834

ORIGINAL REFERENCE NO.: 98:8285a,8288a

TITLE: Construction of pyrimido[5,4-e]-as-triazine, purine, v-triazolo[4,5-d]pyrimidine and pyrazolo[3,4-d]pyrimidine ring systems from 5-aryazo-6-arylidenehydrazino-1,3-dimethyluracils.

AUTHOR(S): Nishigaki, Sadao; Ichiba, Misuzu; Fukami, Kiyoko; Senga, Keitaro

CORPORATE SOURCE: Sch. Med., Keio Univ., Tokyo, 160, Japan

SOURCE: Journal of Heterocyclic Chemistry (1982), 19(4), 769-73

CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal


LANGUAGE: English

IT 54014-88-9P



RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 54014-88-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5,7-dimethyl-3-phenyl-2-(phenylmethyl)- (CA INDEX NAME)




GI




AB Reaction of (aryazo)hydrazinouracils I (R = H, NO₂; R₁ = H, Br, Cl, MeO, MeN), prepared by treatment of hydrazinouracils with diazotized arylamines,

with $\text{Me}_2\text{NCH(OMe)}_2$ gave pyrimidotriazines II, while thermolysis of I gave purines, v-triazolo[4,5-d]pyrimidines, and pyrazolo[3,4-d]pyrimidines instead of the expected II. Mechanisms were proposed for the formation of the various ring systems in these reactions.


ACCESSION NUMBER: 1977:468272 CAPLUS
 DOCUMENT NUMBER: 87:68272
 ORIGINAL REFERENCE NO.: 87:10873a,10876a
 TITLE: Synthesis of pyrazolo[3,4-d]pyrimidines by
 intramolecular cycloaddition of azahexatrienes
 AUTHOR(S): Yoneda, Fumio; Nagamatsu, Tomohisa; Nagamura, Tetsuya;
 Senga, Keitaro
 CORPORATE SOURCE: Fac. Pharm. Sci., Kumamoto Univ., Kumamoto, Japan
 SOURCE: Journal of the Chemical Society, Perkin Transactions
 1: Organic and Bio-Organic Chemistry (1972-1999)
 (1977), (7), 765-7
 CODEN: JCPRB4; ISSN: 0300-922X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 87:68272
 IT 54014-88-9P 54014-89-0P 54014-90-3P
 54014-91-4P 54014-92-5P 54014-93-6P
 54058-37-6P 54058-38-7P 63603-87-2P
 63603-91-8P 63603-92-9P 63603-93-0P
 63603-94-1P 63603-95-2P 63603-96-3P
 63603-97-4P 63603-98-5P
 RL: SPN (Synthetic preparation); PREP (Preparation of
 (preparation of)
 RN 54014-88-9 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5,7-dimethyl-3-phenyl-2-
 (phenylmethyl)- (CA INDEX NAME)



RN 54014-89-0 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-chlorophenyl)-2-[(4-
 chlorophenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)




RN 54014-90-3 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(3,4-dichlorophenyl)-2-
 [(3,4-dichlorophenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)




RN 54014-91-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-((4-methoxyphenyl)methyl)-2-((4-methoxyphenyl)methyl)-5,7-dimethyl- (CA INDEX NAME)




RN 54014-92-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-((4-chlorophenyl)methyl)-2-((4-methoxyphenyl)methyl)-5,7-dimethyl- (CA INDEX NAME)




RN 54014-93-6 CAPLUS


CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[[4-(dimethylamino)phenyl]methyl]-5,7-dimethyl-3-phenyl- (CA INDEX NAME)




RN 54058-37-6 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-phenyl-2-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 54058-38-7 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 63603-87-2 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-[4-(dimethylamino)phenyl]-2-[[4-(dimethylamino)phenyl]methyl]-5,7-dimethyl- (CA INDEX NAME)




RN 63603-91-8 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5,7-dimethyl-3-phenyl-2-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 63603-92-9 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-methoxyphenyl)-2-[(4-methoxyphenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 63603-93-0 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-chlorophenyl)-2-[(4-methoxyphenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 63603-94-1 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5,7-dimethyl-3-phenyl-2-(1-phenylethyl)- (CA INDEX NAME)




RN 63603-95-2 CAPLUS
 CN 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 6-amino-2,5-dihydro-3-phenyl-2-

(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 63603-96-3 CAPLUS

CN 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 6-amino-3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-2,5-dihydro- (9CI) (CA INDEX NAME)




RN 63603-97-4 CAPLUS

CN 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 6-amino-3-(3,4-dichlorophenyl)-2-[(3,4-dichlorophenyl)methyl]-2,5-dihydro- (9CI) (CA INDEX NAME)




RN 63603-98-5 CAPLUS

CN 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 6-amino-2,5-dihydro-3-(4-methoxyphenyl)-2-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




GI




AB Cyclocondensation reaction of aldehyde 1,3-dimethyluracil-6-yl hydrazones with aromatic aldehydes in DMF gave 2,3-disubstituted 5,7-dimethylpyrazolo[3,4-d]pyrimidinediones. E.g., I (R = Me) with PhCHO gave 80% II (R = Me). 6-Benzylidenehydrazino-3-methyluracils with aromatic aldehydes in EtOH and DMF gave diazahexatrienes and 3-aryl-2-benzyl-5-methylpyrazolo[3,4-d]pyrimidinediones, resp. E.g., I (R = H) with PhCHO gave 88% 5-benzylidene-6-benzylidenehydrazino-3-methyluracil (III) and 68% II (R = H). III cyclized to II (R = H) in refluxing DMF. 2-Amino-6-benzylidene-6-benzylidenehydrazino-3-methyluracils with aromatic aldehydes in DMF gave 6-amino-3-aryl-2-benzyl-4-hydroxypyrazolo[3,4-d]pyrimidines. E.g., IV gave V.


ACCESSION NUMBER: 1975:564110 CAPLUS
 DOCUMENT NUMBER: 83:164110
 ORIGINAL REFERENCE NO.: 83:25751a,25754a
 TITLE: Thermolysis and photolysis of 6-(benzylidenehydrazino)uracils. New syntheses of pyrazolo[3,4-d]pyrimidines. Method to convert aldehydes to nitriles
 AUTHOR(S): Yoneda, Fumio; Nagamatsu, Tomohisa
 CORPORATE SOURCE: Fac. Pharm. Sci., Kumamoto Univ., Kumamoto, Japan
 SOURCE: Bulletin of the Chemical Society of Japan (1975), 48(5), 1484-9
 CODEN: BCJSJA8; ISSN: 0009-2673
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 83:164110
 IT 54014-88-9P 54014-89-0P 54014-90-3P
 54014-91-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 54014-88-9 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5,7-dimethyl-3-phenyl-2-(phenylmethyl)- (CA INDEX NAME)



RN 54014-89-0 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)




RN 54014-90-3 CAPLUS
 CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(3,4-dichlorophenyl)-2-[(3,4-dichlorophenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)



RN 54014-91-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-[(4-methoxyphenyl)methyl]-2-[(4-methoxyphenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.

AB The thermolysis of 6-(benzylidenehydrazino)uracil derivs. generally involves their oxidative cyclization to give the corresponding pyrazolo[3,4-d]pyrimidine derivs. I [R, R1 = Me,H; R2 = Ph, p-ClC6H4, p-MeOC6H4, p-(Me2N)C6H4, 3,4-Cl2C6H3]. However, the thermolysis of fully methylated 6-(benzylidenehydrazino)uracil gave no pyrazolo[3,4-d]pyrimidines, but mixts. of the respective nitriles and 1,3-dimethyl-6-methylaminouracil. The photolysis of the fully methylated 6-(benzylidenehydrazino)uracils give the pyrazolo[3,4-d]pyrimidines.

ACCESSION NUMBER: 1974:505449 CAPLUS

DOCUMENT NUMBER: 81:105449

ORIGINAL REFERENCE NO.: 81:16683a,16686a

TITLE: Novel synthetic route to heterocycles via intramolecular cycloaddition of azalogs of hexatriene. New syntheses of purines and pyrazolo[3,4-d]pyrimidines

AUTHOR(S): Yoneda, Fumio; Higuchi, Masatsugu; Nagamatsu, Tomohisa

CORPORATE SOURCE: Fac. Pharm. Sci., Kumamoto Univ., Kumamoto, Japan

SOURCE: Journal of the American Chemical Society (1974), 96(17), 5607-8

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 54014-88-9P 54014-89-0P 54014-90-3P


54014-91-4P 54014-92-5P 54014-93-6P

54058-37-6P 54058-38-7P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)


RN 54014-88-9 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5,7-dimethyl-3-phenyl-2-(phenylmethyl)- (CA INDEX NAME)




RN 54014-89-0 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)




RN 54014-90-3 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(3,4-dichlorophenyl)-2-[(3,4-dichlorophenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)




RN 54014-91-4 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-methoxyphenyl)-2-[(4-methoxyphenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)




RN 54014-92-5 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-chlorophenyl)-2-[(4-methoxyphenyl)methyl]-5,7-dimethyl- (CA INDEX NAME)




RN 54014-93-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 2-[[4-(dimethylamino)phenyl]methyl]-5,7-dimethyl-3-phenyl- (CA INDEX NAME)




RN 54058-37-6 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 5-methyl-3-phenyl-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 54058-38-7 CAPLUS

CN 2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, 3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.

AB The thermolysis of 5-(aryloxy)-1,3-dimethyl-6-[[[(dimethylamino)methylene]amino]uracils gave 8-(dimethylamino)theophylline and 5-aryl-1,3-dimethyl-7-(dimethylamino)-5,6(or 5,8)-dihydro-6-azalumazines. The reaction of 6-amino-1,3-dimethyl-5-(phenylazo)uracil with aromatic aldehydes gave the corresponding 8-aryltheophyllines and 5-aryl-1,3-dimethyl-7-phenyl-5,6(or 5,8)-dihydro-6-azalumazines. This purine synthesis is applicable to other 6-amino-5-(phenylazo)pyrimidines such as 6-amino-1-methyl-5-(phenylazo)uracil and 6-amino-4-hydroxy-2-phenyl-5-(phenylazo)pyrimidine to give the resp. purine derivs. Heating 6-(benzylidene-hydrazino)uracil derivs. with aromatic aldehydes in DMF gave the corresponding 3-aryl-2-benzylpyrazolo[3,4-d]pyrimidine-4,6(5H,-7H)-diones I in excellent yields.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

| | | |
|--|------------|---------|
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 55.46 | 234.49 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| CA SUBSCRIBER PRICE | -8.00 | -8.00 |

STN INTERNATIONAL LOGOFF AT 19:55:37 ON 09 APR 2008